Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 65

1.

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis.

Pàez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Viñals F, Inoue M, Bergers G, Hanahan D, Casanovas O.

Cancer Cell. 2009 Mar 3;15(3):220-31. doi: 10.1016/j.ccr.2009.01.027.

2.

Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited.

Loges S, Mazzone M, Hohensinner P, Carmeliet P.

Cancer Cell. 2009 Mar 3;15(3):167-70. doi: 10.1016/j.ccr.2009.02.007. Review.

3.

Antiangiogenic therapy: impact on invasion, disease progression, and metastasis.

Ebos JM, Kerbel RS.

Nat Rev Clin Oncol. 2011 Mar 1;8(4):210-21. doi: 10.1038/nrclinonc.2011.21. Review. Erratum in: Nat Rev Clin Oncol. 2011;8(4):221. Nat Rev Clin Oncol. 2011 Jun;8(6):316.

5.

The VEGF/Rho GTPase signalling pathway: a promising target for anti-angiogenic/anti-invasion therapy.

van der Meel R, Symons MH, Kudernatsch R, Kok RJ, Schiffelers RM, Storm G, Gallagher WM, Byrne AT.

Drug Discov Today. 2011 Mar;16(5-6):219-28. doi: 10.1016/j.drudis.2011.01.005. Epub 2011 Jan 22. Review.

PMID:
21262381
6.

Growing tumor vessels: more than one way to skin a cat - implications for angiogenesis targeted cancer therapies.

Leite de Oliveira R, Hamm A, Mazzone M.

Mol Aspects Med. 2011 Apr;32(2):71-87. doi: 10.1016/j.mam.2011.04.001. Epub 2011 Apr 22. Review.

PMID:
21540050
7.

The Complexity of Translating Anti-angiogenesis Therapy from Basic Science to the Clinic.

Ye W.

Dev Cell. 2016 Apr 18;37(2):114-25. doi: 10.1016/j.devcel.2016.03.015. Review.

8.

Angiogenesis in cancer - general pathways and their therapeutic implications.

Dimova I, Popivanov G, Djonov V.

J BUON. 2014 Jan-Mar;19(1):15-21. Review.

9.

Antiangiogenic agents in cancer therapy.

Lenz HJ.

Oncology (Williston Park). 2005 Apr;19(4 Suppl 3):17-25. Review.

10.

VEGF in tumor progression and targeted therapy.

Chekhonin VP, Shein SA, Korchagina AA, Gurina OI.

Curr Cancer Drug Targets. 2013 May;13(4):423-43. Review.

PMID:
23167597
11.

The critical role of vascular endothelial growth factor in tumor angiogenesis.

Amini A, Masoumi Moghaddam S, Morris DL, Pourgholami MH.

Curr Cancer Drug Targets. 2012 Jan;12(1):23-43. Review.

PMID:
22111836
12.

The great escape; the hallmarks of resistance to antiangiogenic therapy.

van Beijnum JR, Nowak-Sliwinska P, Huijbers EJ, Thijssen VL, Griffioen AW.

Pharmacol Rev. 2015;67(2):441-61. doi: 10.1124/pr.114.010215. Review.

13.

Role of angiogenesis in tumor growth and metastasis.

Folkman J.

Semin Oncol. 2002 Dec;29(6 Suppl 16):15-8. Review.

PMID:
12516034
14.

Tumor angiogenesis and accessibility: role of vascular endothelial growth factor.

Jain RK.

Semin Oncol. 2002 Dec;29(6 Suppl 16):3-9. Review.

PMID:
12516032
15.

Assessing the in vivo efficacy of biologic antiangiogenic therapies.

Wilson PM, LaBonte MJ, Lenz HJ.

Cancer Chemother Pharmacol. 2013 Jan;71(1):1-12. doi: 10.1007/s00280-012-1978-8. Epub 2012 Oct 9. Review.

PMID:
23053262
16.

Angiogenesis in malignant melanoma.

Felcht M, Thomas M.

J Dtsch Dermatol Ges. 2015 Feb;13(2):125-36. doi: 10.1111/ddg.12580. Review. English, German.

PMID:
25631130
17.

Resistance to antiangiogenic therapies.

Bartolotti M, Franceschi E, Poggi R, Tosoni A, Di Battista M, Brandes AA.

Future Oncol. 2014 Jun;10(8):1417-25. doi: 10.2217/fon.14.57. Review.

PMID:
25052752
18.

Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy.

Veeravagu A, Hsu AR, Cai W, Hou LC, Tse VC, Chen X.

Recent Pat Anticancer Drug Discov. 2007 Jan;2(1):59-71. Review.

PMID:
18221053
19.

Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic.

Ranieri G, Patruno R, Ruggieri E, Montemurro S, Valerio P, Ribatti D.

Curr Med Chem. 2006;13(16):1845-57. Review.

PMID:
16842197
20.

Bevacizumab for advanced breast cancer.

Traina TA, Rugo HS, Dickler M.

Hematol Oncol Clin North Am. 2007 Apr;21(2):303-19. Review.

PMID:
17512451

Supplemental Content

Support Center